Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Circulating MicroRNAs Associated with Type 2 Diabetes

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes…. 

Advertisement

Francisco J. Ortega, Ph.D., and colleagues from the Institut d'Investagacio Biomedica de Girona in Spain studied circulating miRNA in 12 men, six of whom had normal glucose tolerance and the other six who had type 2 diabetes. The association of 10 circulating miRNAs with type 2 diabetes was also verified cross-sectionally in another sample of 45 men with normal glucose tolerance and 48 men with type 2 diabetes. A longitudinal validation was carried out in 35 patients with type 2 diabetes in a randomized, three month long metformin trial. Furthermore, circulating miRNAs were studied in seven healthy participants before and after a six hour hyperinsulinemic-euglycemic clamp and insulin plus intralipid/heparin infusion.

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes. They found that miR-140-5p and miR-423-5p independently accounted for 49.5% of fasting glucose variance after controlling for confounders. These two specific miRNAs along with miR-195 and miR-126 were specific for type 2 diabetes with 89.2% accuracy. Significant reduction in fasting glucose, glycated hemoglobin, and changes in circulating miR-192, miR-140-5p, and miR-22 were seen with metformin but not placebo. Reduction in miR-222 was seen with insulin infusion during clamp, while increases in circulating miR-222 and miR-140-5p were seen with the intralipid/heparin mixture. These results show that there is a close association between circulating miRNAs and type 2 diabetes.

Practice Pearls:
  • Levels of circulating miRNAs vary with insulin action
  • There is an association between circulating miRNAs and type 2 diabetes as they may play a potentially important role in insulin sensitivity

"Circulating MicroRNAs Linked to Type 2 Diabetes."  http://www.ncbi.nlm.nih.gov/pubmed/24478399

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75